Sannula Safe MedTech
Cohort: 3 - Status: Pending


Sannula Safe MedTech is a Jordanian start-up specialized in safety medical solutions. Our
premier product is the Sannula: A safety cannula that promises to solve many problems faced
by health care providers. Our core values are safety, innovation, and trust. Our vision is to
become one of the most innovative medical start-ups that is passionate about safety.
With our innovative design, we created a safety cannula featuring solutions to many problems
that occur during the cannulation process, which put the lives of health care providers and
patients at risk. The problems faced during cannulation are 1) Needle Stick Injury. 2)
Undesirable Blood Backflow. 3) Vein Rupture.
Our product will eliminate the chances of needle stick injury due to the manual safety track,
minimize the chances of vein rupture with our click-fix feature, stop the undesirable blood
backflow with blood control septum, provide optimized control with double face plaster wings
(enabling single hand technique), and ensure more accurate cannulation through new triple
flush back technology.
We have obtained an industrial design protection (EU design patent), and are planning to obtain
full utility patents in Europe and the US.
Sannula is the brainchild of Ziad Abu-Ayyash whose background in the medical field inspired
him to create solutions to problems he faced first hand. Moataz Mukhaimer (MBA) joined
Sannula as a partner with over 15 years of experience in consulting. Our team strongly believes
in the mission of Sannula and we are determined to succeed in our venture.
The global peripheral intravenous catheters market is valued at US$ 4.9 billion in 2020 with
CAGR of 7% for the period 2020 -2030. North America and Europe account for 70% of the
market value, with safety PIVC technology leading the growth1
Our target market is hospitals and clinics primarily in Europe and North America. We plan on
launching in France where there are over 3,0462 hospitals in the country and favorable tax
We are a B2B business outsourcing the manufacturing and distribution to industry experts. Our
core operational systems revolve around research & development, marketing & sales, and
strategic management.
The start-up costs for Sannula Safe MedTech are projected at Euro 480,0003
, divided into Prelaunch cost of Euro 204,500 and Operating cash flow cost of Euro 269,370. By year three, the
projected revenue will be Euro 2,657,813 and net profit is projected at Euro 1,063,631.

Solution stage: Widely implemented
Attachments for more info

Sustainability factors

“Industry Profile
Current Size
The global peripheral intravenous catheters market is valued at US$ 4.9 billion in 2020. Studies
show that North America and Europe account for 70% of the market value, and Safety PIVC
technology accounts for the highest market value share in global peripheral intravenous
catheters market, due to the rising demand for safe devices5
Growth Potential
The health industry in general is always growing as the population grows. It is a complex and
vital industry with many players: governments, pharmaceutical companies, research institutions,
hospitals, insurance companies, and manufacturers. The expected peripheral intravenous
catheters market CAGR is 7% for the 2020 to 2030 period6
, with safety PIVC technology leading
the growth. The COVID-19 global crises emphasized the importance of medical solutions that
are both innovative and safe.
Industry Trends
The following are some industry trends observed through research:
1) There is a clear shift towards safety cannulas (Vs. conventional) especially in Europe
and North America.
2) The importance of medical funding (for both research and production) is increasing and
governments are investing more in the industry.
3) Technological solutions such as medical software and Artificial Intelligence are
presenting promising opportunities for companies in the medical industry.
Other Characteristics
This is a highly scalable business that is not effected by seasonality (except sudden increased
demand due to a health outbreak such as COVID-19). The manufacturing costs are low and the
gross margins average around 70-80%.
Distribution Channels
In general, the medical hardware industry in both Europe and North America has medical
distribution companies that sell directly to hospitals and medical institutions. Our team will work
with our distributor to promote, raise awareness, educate, and train medical health providers on
our products.
We have researched and contacted some distribution companies in France, and the feedback
on our product has been encouraging.
Our competitive Advantages are:
Blood control septum. This is a mechanism to help stop the blood backflow from contaminating
the surrounding environment via a 4-way close system valve, which controls the fluids in and
out of the vein and provides the daily care port as well to clear the Cannula.
Research shows that direct cost analysis, including clinician time, demonstrated that the
introduction of SPIVC with multi-use blood control septum could offer time efficiency savings
equivalent to a reduction in average cannulation costs by 25%. 82% of users perceived the
insertion of SPIVC with multi-use blood control septum to be easy to use; 82% would choose to
use it in clinical practice.7
Triple flush-back technology. This feature helps health care providers track the insertion process
of the IV cannula to ensure successful insertion.
Due to the insufficient blood tracking system in the short PIVC the “First attempt PIVC insertion
failure rates can be up to 35-40% for adults 1,2 and between 50–65% for children 1,3; with a
concerning 10% of adults and a quarter of all children experiencing more than four attempts at
of vein rupture and failure of cannulation.
Research indicates that dislodgement can occur when IV catheter is incorrectly secured with
standard medical tape or another adhesive securement device. IV dislodgement can lead to an
unscheduled IV restart or more invasive central line. Dislodgement rate has been reported in the
range of 3.7–9.9% in a prospective randomized study with a mean of 6.9%. Even a greater rate
of 17.5% was observed in prospective observational studies. At almost 10% dislodgement rate,
financial dislodgement burden can be tremendous translating to 33 million, if approximately 330
million IV catheters are sold in the USA.9
Market Analysis
Target Market Profile
Our target market is hospitals and clinics primarily in Europe and the US. We plan on launching
in France where there are 3,046 hospitals with a capacity of 933,86510 beds. More specifically,
we will launch in the Paca region (Southern France) where they offer many benefits to start-ups
and entrepreneurs.
France is second in Europe for medical devices revenues after Germany (MedTech Europe,
2019), with the sector covering products and equipment in a wide range of fields, from syringes
and in-vitro diagnostics to MRI scanners. There are more than 1,340 companies in the French
medical device sector, 92% of which are SMEs, generating revenues of €28 billion, with €8
million from exports (National Medical Technology Industry Association (SNITEM), 2018).
In 2018, France’s medical device exports almost reached €7.5 billion, up 2.2%, with Europe the
main destination for more than half of exports. France’s main customers are the United States
(12% of exports), Germany (12%) and the Netherlands (11%) (French Customs Authorities).
France accounts for 3.4% of global exports of medical devices. (Global Trade Atlas / IHS
Customer Profile
Our customer profile is hospitals and clinics in countries where safety medical solutions already
exist and are growing fast. Our customer values the safety of their employees and patients and
understands the costs and health risks associated with using conventional cannulas due to
increased chances of infections.
Future Markets
Sannula Safe MedTech will launch in France and we will expand into various European markets
such as Germany and Belgium. This highly depends on our success but also on the markets
available through our distribution partners.
The US market is very attractive (despite high competition). It is in our strategic plan to apply for
the FDA approval. Once we achieve significant positive cash flow, we will invest in marketing
our products in the US and forming partnerships with distributors. “

Contact details

Ziad Hassan Abu Ayyash, CEO & Founder


Location: Amman
Age: 0 - 2 Year
Number of employees: 2

Expectation from TechAid

Access to Finance:
Looking for 250K to 500K as Investment
Inline Feedbacks
View all comments